skip to main content
OSTI.GOV title logo U.S. Department of Energy
Office of Scientific and Technical Information

Title: Hemin as a generic and potent protein misfolding inhibitor

Journal Article · · Biochemical and Biophysical Research Communications
 [1];  [2]; ;  [1];  [3]
  1. School of Chemistry and Physics, The University of Adelaide, Adelaide, SA 5005 (Australia)
  2. Discipline of Pharmacology, The University of Adelaide, Adelaide, SA 5005 (Australia)
  3. Research School of Chemistry, The Australian National University, Canberra, ACT 0200 (Australia)

Highlights: • Hemin prevents Aβ42, α-synuclein and RCM-κ-casein forming amyloid fibrils. • Hemin inhibits the β-sheet structure formation of Aβ42. • Hemin reduces the cell toxicity caused by fibrillar Aβ42. • Hemin dissociates partially formed Aβ42 fibrils. • Hemin prevents amorphous aggregation by ADH, catalase and γs-crystallin. - Abstract: Protein misfolding causes serious biological malfunction, resulting in diseases including Alzheimer’s disease, Parkinson’s disease and cataract. Molecules which inhibit protein misfolding are a promising avenue to explore as therapeutics for the treatment of these diseases. In the present study, thioflavin T fluorescence and transmission electron microscopy experiments demonstrated that hemin prevents amyloid fibril formation of kappa-casein, amyloid beta peptide and α-synuclein by blocking β-sheet structure assembly which is essential in fibril aggregation. Further, inhibition of fibril formation by hemin significantly reduces the cytotoxicity caused by fibrillar amyloid beta peptide in vitro. Interestingly, hemin degrades partially formed amyloid fibrils and prevents further aggregation to mature fibrils. Light scattering assay results revealed that hemin also prevents protein amorphous aggregation of alcohol dehydrogenase, catalase and γs-crystallin. In summary, hemin is a potent agent which generically stabilises proteins against aggregation, and has potential as a key molecule for the development of therapeutics for protein misfolding diseases.

OSTI ID:
22416830
Journal Information:
Biochemical and Biophysical Research Communications, Vol. 454, Issue 2; Other Information: Copyright (c) 2014 Elsevier Science B.V., Amsterdam, The Netherlands, All rights reserved.; Country of input: International Atomic Energy Agency (IAEA); ISSN 0006-291X
Country of Publication:
United States
Language:
English

Similar Records

α-Synuclein aggregation, seeding and inhibition by scyllo-inositol
Journal Article · Fri Jan 15 00:00:00 EST 2016 · Biochemical and Biophysical Research Communications · OSTI ID:22416830

Amyloid fibril formation of peptides derived from the C-terminus of CETP modulated by lipids
Journal Article · Fri Apr 26 00:00:00 EDT 2013 · Biochemical and Biophysical Research Communications · OSTI ID:22416830

Controlled and Selective Photo-oxidation of Amyloid-β Fibrils by Oligomeric p-Phenylene Ethynylenes
Journal Article · Mon Mar 28 00:00:00 EDT 2022 · ACS Applied Materials and Interfaces · OSTI ID:22416830